Trial Profile
Ranolazine pretreatment in patients with coronary artery disease undergoing elective percutaneous coronary intervention
Status:
Not stated
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2011
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Myocardial infarction; Myocardial reperfusion injury
- Focus Therapeutic Use
- 15 Dec 2011 Results of this trial are expected by 2012.
- 07 Dec 2011 New trial record